Login
Super Investors GordonMD Global Investments LP
GG

GordonMD Global Investments LP

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$166M
Positions
14
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (4 quarters reported)

$207M $139M
Q4 25 Q1 26 Q2 26 Q3 26

$139M in Q4 2025 → $166M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
PO Pyxis Oncology Inc 21.8% Added 55% 15,541,909 $36.2M
Kyverna Therapeutics Inc 18.5% Added 6.5% 4,521,318 $30.7M
TP Teva Pharmaceutical Inds Ltd 9.0% New 379,520 $15M
CT Celldex Therapeutics Inc New 5.4% Unchanged 279,720 $9.07M
Tango Therapeutics Inc 5.4% New 1,852,495 $9.02M
Vir Biotechnology Inc 5.4% Trimmed 41% 803,552 $8.98M
Adarx Pharmaceuticals Inc 5.4% New 450,000 $8.97M
AT Allogene Therapeutics Inc 5.1% Unchanged 5,298,000 $8.48M
BP Bausch Plus Lomb Corp 4.9% Trimmed 17% 475,472 $8.08M
Editas Medicine Inc 4.8% Unchanged 3,127,000 $8.04M
Incyte Corp 3.7% Added 18% 51,080 $6.2M
Taysha Gene Therapies Inc 3.7% Trimmed 66% 248,000 $6.19M
Amgen Inc 3.7% Trimmed 28% 14,512 $6.12M
SR Scholar Rock Hldg Corp 3.2% Trimmed 17% 110,500 $5.34M

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 3 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
TP Teva Pharmaceutical Inds Ltd Exited −2,402,495 −$16.4M —
TP Teva Pharmaceutical Inds Ltd New +379,520 +$15M 9.0%
PO Pyxis Oncology Inc Added +5,517,000 +$12.9M 21.8%
Taysha Gene Therapies Inc Trimmed −475,185 −$11.9M 3.7%
UP Ultragenyx Pharmaceutical In Exited −289,101 −$9.65M —
Tango Therapeutics Inc New +1,852,495 +$9.02M 5.4%
Adarx Pharmaceuticals Inc New +450,000 +$8.97M 5.4%
Vir Biotechnology Inc Trimmed −550,000 −$6.15M 5.4%
Sionna Therapeutics Inc Exited −136,000 −$5.98M —
CP Crinetics Pharmaceuticals In Exited −126,985 −$4.75M —

Showing the 10 largest of 16 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
PO Pyxis Oncology Inc Added +5,903,039 +$17.8M 14.6%
Editas Medicine Inc New +3,127,000 +$10.1M 4.9%
AT Allogene Therapeutics Inc Added +3,868,000 +$8.05M 5.3%
TP Teva Pharmaceutical Inds Ltd Added +1,145,000 +$7.8M 7.9%
CT Celldex Therapeutics Inc New Added +109,413 +$4.07M 5.0%
Tarsus Pharmaceuticals Inc Exited −42,680 −$2.99M —
Vir Biotechnology Inc Trimmed −165,000 −$1.68M 6.7%
Taysha Gene Therapies Inc Trimmed −14,365 −$487K 11.9%

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
Taysha Gene Therapies Inc Trimmed −593,351 −$17.9M 15.5%
SR Scholar Rock Hldg Corp New +132,500 +$6.51M 4.5%
Sionna Therapeutics Inc New +136,000 +$5.45M 3.8%
Vir Biotechnology Inc Added +588,235 +$5.27M 9.5%
CP Crinetics Pharmaceuticals In Trimmed −97,150 −$3.53M 3.2%
AT Allogene Therapeutics Inc New +1,430,000 +$3.49M 2.4%
TP Teva Pharmaceutical Inds Ltd Added +487,945 +$2.18M 3.9%
Tarsus Pharmaceuticals Inc Trimmed −24,000 −$1.68M 2.1%
Kyverna Therapeutics Inc Trimmed −147,000 −$1.27M 25.5%
Amgen Inc Trimmed −3,000 −$1.06M 5.0%

Showing the 10 largest of 13 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support